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Abstract
As of 20 May 2016 there have been 28,646 cases and 11,323 deaths resulting from the West African Ebola virus
disease (EVD) outbreak reported to the World Health Organization. There continue to be sporadic flare-ups of EVD
cases in West Africa.
EVD presentation is nonspecific and characterized initially by onset of fatigue, myalgias, arthralgias, headache, and
fever; this is followed several days later by anorexia, nausea, vomiting, diarrhea, and abdominal pain. Anorexia and
gastrointestinal losses lead to dehydration, electrolyte abnormalities, and metabolic acidosis, and, in some patients,
acute kidney injury. Hypoxia and ventilation failure occurs most often with severe illness and may be exacerbated
by substantial fluid requirements for intravascular volume repletion and some degree of systemic capillary leak.
Although minor bleeding manifestations are common, hypovolemic and septic shock complicated by multisystem
organ dysfunction appear the most frequent causes of death.
Males and females have been equally affected, with children (0–14 years of age) accounting for 19 %, young adults
(15–44 years) 58 %, and older adults (≥45 years) 23 % of reported cases. While the current case fatality proportion
in West Africa is approximately 40 %, it has varied substantially over time (highest near the outbreak onset)
according to available resources (40–90 % mortality in West Africa compared to under 20 % in Western Europe and
the USA), by age (near universal among neonates and high among older adults), and by Ebola viral load at
admission.
While there is no Ebola virus-specific therapy proven to be effective in clinical trials, mortality has been dramatically
lower among EVD patients managed with supportive intensive care in highly resourced settings, allowing for the
avoidance of hypovolemia, correction of electrolyte and metabolic abnormalities, and the provision of oxygen,
ventilation, vasopressors, and dialysis when indicated. This experience emphasizes that, in addition to evaluating
specific medical treatments, improving the global capacity to provide supportive critical care to patients with EVD
may be the greatest opportunity to improve patient outcomes.
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Background
In December 2013, transmission of Zaire ebolavirus
(Ebola virus (EBOV)) to humans occurred in southeastern
Guinea [1], spreading to Liberia and Sierra Leone and rap-
idly surpassing the cumulative total of previous Ebola
virus disease (EVD) outbreaks [2, 3]. Prior outbreaks oc-
curred primarily in remote, resource-challenged settings,
with case fatality proportions of 50–88 % [4]. This current
outbreak, due to its size and spread in West Africa, in
addition to exported and medically evacuated cases to
Europe and North America, has engaged a much broader
health worker community, including critical care clini-
cians. While the clinical manifestations, duration of ill-
ness, and transmissibility appear similar to previous EVD
outbreaks [1, 5–9], with the availability and provision of
advanced supportive care in Europe and North America,
mortality was less than 20 %, emphasizing the potential
importance of supportive and critical care in the manage-
ment of EVD patients. This review provides an up-to-date
examination of EVD using the knowledge gained during
the 2013–2016 West African outbreak to highlight rele-
vance for the critical care physician.
Viral hemorrhagic fevers
Viral hemorrhagic fever describes the syndrome of acute
severe febrile illness caused by over 30 viruses from four
different taxonomic families—Filoviridae, Arenaviridae,
Bunyaviridae, and Flaviviridae. Although they differ in
disease epidemiology, transmission, and pathogenesis,
most of these RNA viruses are zoonotic and cause non-
specific symptoms including fever, headache, weakness,
vomiting, and diarrhea. Infection with filoviruses, includ-
ing Marburg and Ebola viruses, can be associated with a
rapid progression to hemodynamic instability, shock, and
multiorgan dysfunction [4, 8].
Filoviruses were discovered in 1967 when 31 labora-
tory workers became ill after coming into contact with
green monkeys imported from Africa [10]. The newly
discovered virus killed 23 % of infected workers in the
German town of Marburg. Ebola virus was discovered in
1976 during simultaneous outbreaks in Zaire and Sudan
in which 88 % and 53 % of patients died, respectively
[2, 11, 12]. Since its discovery there have been approxi-
mately 25 EVD outbreaks [3].
Epidemiology
The West African EVD outbreak was first recognized in
March 2014 in the forested region of southeastern
Guinea. However, the first EVD case may have happened
as early as December 2013 with zoonotic transmission
of EBOV from an animal to a human, and subsequent
human-to-human spread [1]. Transmission was likely
well underway throughout West Africa in the spring of
2014 [13]. By June 2014 there were a few hundred
confirmed or probable EVD cases, 3000 by the end of
August—outstripping the ability of providers at existing
Ebola treatment units to isolate and care for patients—and
eventually over 20,000 cases by the end of December 2014
[14]. As of 20 May 2016 there have been 28,610 reported
confirmed, probable, and suspected EVD cases and 11,308
deaths in Guinea, Sierra Leone and Liberia [15]. Another 36
cases have primarily received care in Mali, Senegal, and
Nigeria as well as countries outside Africa including the
USA, UK, Germany, Spain, France, Italy, the Netherlands,
Norway, and Switzerland (Table 1) (Additional file 1). EVD
cases in West Africa have been reported equally among
males and females, with children (0–14 years of age)
accounting for 19 %, young adults (15–44 years) 58 %, and
older adults (≥45 years) 23 % of reported cases [5, 6, 16].
Characteristics of transmission
Person-to-person transmission of EBOV occurs through
mucous membrane contact with bodily fluids (e.g.,
vomit, feces, and blood) from those who are infected
and symptomatic or by touching the body of someone
who died of EVD [17]. Droplet transmission is less likely
to occur due to low prevalence of respiratory symptoms
[16, 18]. While there are animal transmission models of
aerosolized EBOV [19, 20], the clinical relevance of small
particle droplet nuclei transmission is unclear and may
only apply to the care of critically ill patients undergoing
aerosol-generating procedures (intubation and ventilation,
bronchoscopy) [18]. Percutaneous transmission with
sharps (needle-stick, glass-related exposure) contaminated
with infected bodily fluids is thought to be a very efficient
mechanism of Ebola virus transmission [11].
Infection prevention and control practices
The concern about EBOV transmission has positioned
infection prevention and control (IPC) at the center of
clinical care. Theoretically, meticulous provision of con-
tact precautions (hand washing, the use of gloves and a
gown along with protection against mucus membrane
(eyes, nose, and mouth) exposure, and proper donning
and doffing of all personal protective equipment (PPE))
should be sufficient to prevent nosocomial EBOV trans-
mission. In nonclimate-controlled West African Ebola
treatment facilities (Fig. 1), the heat and humidity pre-
vent optimal functioning of medical masks and some
duckbill N-95 respirators (humidity and sweat cause
them to sag and collapse). Tight fitting goggles often
fog, reducing visibility. Face shields afford improved visi-
bility but must provide sufficient coverage without risk
of splash-related facial exposure. Half-sphere, semi-rigid
respirators tend to be more resistant to moisture-related
collapse and deformation. However, concern about the
high mortality of EVD has led to IPC and PPE choices
in the field that sometimes do not follow traditional
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infection control recommendations or guidance from
international technical organizations. This has often re-
sulted in PPE that cannot be safely tolerated by healthcare
personnel for more than 45–60 min due to excessive heat
and humidity [21], risking syncope, potentially dangerous
behaviour (e.g., adjusting fogged facial protection with
soiled gloves), and inability to safely perform tasks such as
insertion of intravenous catheters. In West Africa, Ebola
virus transmission likely also occurs among healthcare
personnel during informal healthcare provision in the com-
munity to patients or colleagues, without appropriate infec-
tion prevention and control practice [22, 23]. Nosocomial
EBOV transmission in Spain [24, 25] and the USA [26]
similarly reinforces the importance of rigorous Ebola IPC
practices and healthcare personnel training, irrespective of
the healthcare system [27, 28].
Table 1 Chronological demographic description of 27 Ebola virus disease patients treated outside West Africa (August 2014–May
2015)
Age
(years)
Occupation Country where Ebola
virus infection occurred
Case presentation Country of Hospitalisation Hospital LOS
(days)
Outcome
1a 33 Health worker Liberia Medically evacuated USA 19 Survived
2a 59 Health worker Liberia Medically evacuated USA 14 Survived
3 75 Non health worker Liberia Medically evacuated Spain 5 Died
4 29 Health worker Sierra Leone Medically evacuated UK 10 Survived
5a 36 Health worker Sierra Leone Medically evacuated Germany 30 Survived
6a 51 Health worker Liberia Medically evacuated USA 20 Survived
7a 43 Health worker Sierra Leone Medically evacuated USA 41 Survived
8 N/A Health worker Liberia Medically evacuated France 16 Survived
9 70 Nonhealth worker Sierra Leone Medically evacuated Spain 3 Died
10a 45 Unknown Liberia Imported infection USA 8 Died
11a 38 Health worker Sierra Leone Medically evacuated Germany 47 Survived
12a 44 Health worker Spain Secondary infection Spain 30 Survived
13a 33 Nonhealth worker Liberia Medically evacuated USA 16 Survived
14 30 Health worker Sierra Leone Medically evacuated Norway 13 Survived
15 56 Health worker Liberia Medically evacuated Germany 6 Died
16a 26 Health worker USA Secondary infection USA 13 Survived
17a 29 Health worker USA Secondary infection USA 14 Survived
18 33 Health worker Guinea Imported infection USA 19 Survived
19 N/A Nonhealth worker Sierra Leone Medically evacuated France 21 Survived
20a 44 Health worker Sierra Leone Medically evacuated USA 2 Died
21a 43 Health worker Sierra Leone Medically evacuated Switzerland 15 Survived
22 50 Health worker Sierra Leone Medically evacuated Italy 38 Survived
23 N/A Nonhealth worker Liberia Medically evacuated Netherlands 13 Survived
24 39 Health worker Sierra Leone Imported infection UK 25 Survived
25 25 Health worker Sierra Leone Medically evacuated UK 15 Survived
26 N/A Health worker Sierra Leone Medically evacuated USA 27 Survived
27 N/A Health worker Sierra Leone Imported infection Italy 31 Survived
aMedical management (including utilization of invasive therapies) is described in peer-reviewed format (Table 3) and in reference [40]
LOS length of stay (days), N/A not available
Fig. 1 West African Ebola Treatment Facility—April 2014
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Pathophysiology
The pathogenesis of EVD in humans remains poorly
understood but shows similarities with, and differences
from, other causes of viral hemorrhagic fever or bacterial
sepsis. End-organ dysfunction seems to result from a
combination of a direct viral cytopathic effect, the host
immune response, and from under-resuscitated hypovol-
emic shock [5, 6]. EBOV binds to lectins and other surface
receptors, with monocytes, macrophages, and dendritic
cells as targets. These virus-containing cells spread
through the lymphatic system, liver, and spleen, resulting
in a widely disseminated viral infection [29, 30]. Endothe-
lial cell infection and activation may lead to increased
levels of soluble adhesion molecules, thombomodulin, and
inflammatory mediators such as interferon-gamma and
-alpha, interleukins (IL)-2, 6, and 10, interferon-inducible
proteins, and tumor necrosis factor alpha [29, 30], result-
ing in vascular injury.
Thrombocytopenia, consumption, and reduced pro-
duction of clotting factors, in addition to increased
concentrations of fibrin degradation products in pa-
tients with severe EVD, may contribute to bleeding
[29, 30]. Hepatocellular inflammation is common, and
myositis with elevations of creatine kinase and pancreatitis
(elevated blood amylase and lipase levels) occurs in severe
cases [29, 30].
While acute kidney injury can often be explained by
under-resuscitated hypovolemia, it might also arise
from viral or secondary bacterial sepsis, acute tubular
necrosis, myoglobinuria, and microvascular renal
thrombi associated with sepsis or disseminated intra-
vascular coagulation [29, 30]. Adrenal gland viral infec-
tion has been shown in animal models and might
contribute to hypotension, renal sodium loss, and
hypovolemia [30].
Diagnostics
Diagnostic testing is recommended when a patient ex-
hibits symptoms meeting the EVD case definition [31].
Ebola viral RNA can be detected in clinical specimens
by real-time reverse transcription polymerase chain re-
action (RT-PCR); if the virus is detected by a specific
antigen diagnostic test or by detection of IgM anti-
bodies directed against EBOV, RT-PCR should be used
for confirmation [31, 32]. Because the sensitivity of mo-
lecular tests depends on Ebola viral loads, specimens
collected within 3 days of symptom onset may be
falsely negative due to undetectable viremia early in the
clinical course. In these circumstances, another blood
specimen for RT-PCR testing should be collected 3 days
after symptom onset [33]. Point-of-care rapid diagnos-
tic tests (RDTs) have been tested in the field, but they
lack sensitivity, require a cold chain, and remain under
evaluation in clinical trials [34].
Clinical presentation of Ebola virus disease
The clinical presentation of EVD falls along a spectrum
ranging from minimally symptomatic infection [8] to se-
vere illness with hemorrhagic complications, shock, mul-
tiorgan dysfunction, and death. The incubation period
ranges from 2 to 21 days but may depend on the mode
of transmission [4]: 5–7 days following a percutaneous
inoculation and a mean of 9 days following direct mucus
membrane contact with infected bodily fluids [8, 30, 35].
EVD typically begins with nonspecific initial signs and
symptoms including fever, fatigue, weakness, and head-
ache, similar to many infectious diseases in sub-Saharan
Africa, often leading to a missed diagnosis and contin-
ued transmission. A fleeting maculopapular rash can be
seen within the first week [36, 37]. Gastrointestinal symp-
toms (nausea, vomiting, abdominal pain, and diarrhea)
usually follow 4–6 days after illness onset and can lead
to hypovolemia and shock with multisystem organ dys-
function. Gastrointestinal losses and anorexia can precipi-
tate hypokalemia, metabolic acidosis, and acute kidney
injury [6]. Hypoxia and ventilation failure tend to occur
with severe illness and may be exacerbated by vascular in-
jury and accompanying large-volume fluid requirements
[38]. Serious hemorrhagic complications are relatively rare,
while more mild bleeding may occur in approximately 30 %
of cases [5, 6, 9, 16, 39, 40]. Delirium and encephalopathy
or encephalitis may reflect metabolic encephalopathy or
direct neuroinvasion and hiccups may be of central or per-
ipheral neurological origin [5, 30, 41, 42].
Clinical outcomes
While the cumulative case fatality proportion in West
Africa is approximately 40 % as of May 2016, it has
varied substantially during the course of the outbreak
(being higher near the beginning). In comparison, the
cumulative case fatality proportion for patients treated
in Western Europe and the USA during 2014–2015
was 18.5 % [40] (Table 2). Case fatality remains highest
among young children and older adults [5, 6, 16, 43].
Pregnant women often experience spontaneous abortion
Table 2 Demographic and outcome summary of 27 Ebola virus
disease patients treated outside West Africa
All Survived Died
Treated outside West Africa 27 22 (81.5 %) 5 (18.5 %)
Gendera (male) 17 (68 %) 12 (60 %) 5 (100 %)
Median ageb (range) 40.5 (25–75) 36 (25–59) 56 (42–75)
Mean hospital length of stay
(days, confidence interval)
19 (±11.5) 22 (±10.2) 5 (±2.4)
Evacuated from West Africa 20 (74 %) 16 (80 %) 4 (20 %)
Infected outside West Africa 3 (11 %) 3 (100 %) 0
aGender available for 25 patients
bAge available for 22 patients
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followed by bleeding, as well as preterm labor and still-
birth if Ebola virus infection occurs later in pregnancy.
Vertical transmission and subsequent neonatal mortality
has been virtually uniform in the few documented live
births by women with acute EVD [44]. A high Ebola viral
load at time of admission is associated with more severe
illness and mortality [5, 6, 29, 43, 45–47], with other
markers of organ dysfunction variably associated with out-
comes [6, 8, 29, 48].
Monitoring and care delivery
The management of critically ill EVD patients in a
resource-constrained setting has historically been re-
stricted to variable monitoring of daily clinical signs and
symptoms without access to continuous assessment [8].
The need for strict IPC practices and separation of pa-
tient care areas in West Africa significantly limited
documentation and review of daily clinical records both
inside and outside of high-risk patient care. As the case
burden decreased and the ratio of healthcare personnel
to patients increased, assessments were performed more
systematically at some Ebola treatment facilities, with
temperature, heart rate, blood pressure, respiratory rate,
pulse oximetry, qualitative descriptions of urine, and
gastrointestinal output, as well as fluid balance estimation.
Laboratory data other than Ebola RT-PCR results were
essentially unavailable at Ebola treatment facilities in
West Africa early in the outbreak [33, 49, 50]. Initially,
there was very limited attention to diagnostics other
than Ebola RT-PCR. The point-of-care systems for mon-
itoring biochemistry and hematology parameters, such
as the i-STAT® or the Piccolo Xpress®, were inconsist-
ently utilized inside Ebola treatment facilities [5, 6, 48],
in part due to limited manufacturer-recommended
temperature and humidity ranges. Over the course of
the West African outbreak, with support from national
and deployed international laboratories, basic biochemis-
try, blood counts, and coagulation profiles helped to
characterize the course of illness, but remained inconsist-
ently available and often with substantial delays in results
reporting due to transport and processing time. Malaria
rapid diagnostic tests, and less commonly RT-PCR, were
available at most of the laboratories that supported Ebola
treatment facilities in West Africa. However, testing for
Lassa fever virus (endemic in EBOV-affected countries) or
other causes of sepsis was not routine.
Bedside ultrasonography has not been widely deployed
[51] but could help with assessing volume status, responsive-
ness to intravenous fluids [50], and assessment of challen-
ging clinical signs such as abdominal distension [42]. Plain
chest and abdomen radiography has been performed in
European and North American settings [52] but has rarely
been available to patients with Ebola in West Africa.
Among patients treated in the USA and Europe,
pulmonary edema has been reported in 44 % and acute re-
spiratory distress syndrome in another 22 % [40].
Discharge criteria and virus persistence during
convalescence
The World Health Organization (WHO) recommends
considering discharge of patients from isolation on the
basis of a negative blood Ebola virus RT-PCR result
taken at least 3 days after the resolution of symptoms
[33, 41]. However, Ebola virus can persist in certain body
fluids after it is undetectable in the blood and after clin-
ical recovery from EVD [42, 53–56]. Viable Ebola virus
has been isolated from urine, semen, cerebrospinal fluid,
and vitreous humor many months after blood clearance
[42, 56–61], suggesting that some activities (unprotected
sex, invasive procedures, or penetrating eye trauma)
confer a transmission risk even after symptoms and
viremia resolve. It is therefore critical to counsel EVD
survivors about the risks of Ebola virus persistence
[59, 60] and appropriate precautions after discharge, in-
cluding barrier protection during sexual intercourse [50]
until semen has tested negative for Ebola virus twice, or
for at least 6 months after EVD onset [62]. Health
workers and others should continue to apply standard
precautions, as with all patients, when evaluating EVD
survivors in the convalescent period. Additional infec-
tion prevention and control practices, based upon an in-
dividual patient risk assessment, may be prudent for
specific procedures in convalescence, even when there is
no detectable EBOV in the blood (e.g., lumbar puncture
or vitreous humor sampling) [63].
Critical and supportive care interventions
Providing supportive care to critically ill patients with
EVD in resource-poor settings is challenging [64] due to
limited infrastructure, lack of materials and trained
healthcare personnel, and uncertainty regarding the
translation of modern sepsis treatment strategies [65]
and optimal intravenous fluid management protocols in
the absence of advanced monitoring used in resource-
rich settings [66]. Respiratory symptoms such as cough
are not a prominent feature of EVD and tachypnea likely
represents respiratory compensation of severe metabolic
acidosis [9, 30, 50]. Translating fluid resuscitation proto-
cols used in a resource-rich setting [42] to settings
where supplemental oxygen therapy is not routinely
available [49], in a disease with possible vascular leak
syndrome [38], could result in increased morbidity [67]
and warrants further investigation [68–70]. The use of
antibiotics is common at Ebola treatment facilities [5, 6]
before the diagnosis of EVD is confirmed in febrile
patients and as empiric treatment of potential bacterial
co-infection or gastrointestinal bacterial translocation in
patients with confirmed EVD [9]. However, disruption of
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gastrointestinal flora due to broad-spectrum antibiotics
could exacerbate diarrhea and fluid losses. Symptomatic
treatment of severe diarrhea with loperamide was vari-
ably employed across Ebola treatment facilities. The
risks and benefits of these practices warrant evaluation
with observational studies and clinical trials [71].
Early and during the peak of the outbreak, clinical
management was generally limited to supportive care fo-
cusing on aggressive oral and occasional intravenous
volume resuscitation. As the case numbers decreased,
advanced care became more common in some treatment
facilities. Despite the limitations of working in PPE,
feasibility and safety of central venous catheter placement
was demonstrated at a UK military-supported treatment
facility in Kerry Town, Sierra Leone [72]. Feasibility of
transthoracic echocardiography was demonstrated at a
military Ebola treatment facility in Conakry, Guinea [51].
By mid-December 2014, EMERGENCY, an Italian non-
governmental organization, established an Ebola critical
care unit in Lakka and Goderich, Sierra Leone, the latter
consisting of constant bedside nursing, continuous blood
pressure, heart rate, respiratory rate monitoring, pulse
oximetry, arterial and venous cannulation, nasogastric
tube feeding, invasive ventilation, continuous renal re-
placement therapy, diagnostic biochemistry and
hematology, ultrasonography, and plain radiography
(Fig. 2). With waning case numbers, accurate evaluation
of the impact of these interventions on patient out-
comes has not been possible. Other sites, such as the
GOAL-supported Mathaska Ebola Treatment Unit (ETU)
and the Partners in Health-supported Maforki ETU in Si-
erra Leona also began using aspects of critical care
procedures by February 2015, including nasogastric tube
feeding, bedside ultrasound, as well as intraosseus cannu-
lation for intravenous fluid resuscitation [73].
The historical philosophy of providing only oral fluids
for EVD care has given way to the delivery of context-
appropriate critical care [38, 42, 74–79]. To date, 27 pa-
tients managed in nine countries outside of West Africa
(Table 1) have been described, with a survival of 81.5 %
[40] (Table 2). Thirteen detailed accounts of EVD man-
agement in modern healthcare settings in the USA,
Germany, Spain, and Switzerland provide insight into
the course of the illness [38, 42, 76–82] (Table 3). These
case reports confirm that intensive care monitoring in
appropriately prepared centers is feasible. Noninvasive
ventilation [38, 42], mechanical ventilation [38, 78, 81],
central venous catheter insertion for vasopressor support
[38, 42, 78, 79, 82], and renal replacement therapy
[38, 78, 81, 82] can be provided effectively and safely
(Table 3, Figs. 3 and 4) [83].
Establishing supportive and critical care services
in highly resourced settings
While it may be advisable to concentrate or regionalize
care for patients with EVD in specific hospitals, any
health centre should be prepared to safely take a focused
and relevant history from a patient with an infectious
syndrome, and to mobilize the appropriate local and re-
gional response. Many hospitals, even if not EVD refer-
ral centers, may be asked to care for patients until initial
(and possibly subsequent) blood Ebola RT-PCR results
are known. Therefore, it is essential that hospital staff
are well trained and familiar with recommended IPC
practices (and for EVD, standard and contact IPC pre-
cautions in particular). It is ideal to have an on-call
inter-professional team who have undergone training in
Ebola-specific IPC training.
While practiced IPC protocols are important to keep
health workers safe, a very common clinical pitfall is to
equate IPC practices with care. While Ebola-specific
standardized IPC protocols are absolutely necessary,
there will be situations requiring patient-specific IPC
risk-assessments—most commonly involving patients at
the beginning of, or in the convalescent phase of, their
illness with minimal symptoms and no vomiting or diar-
rhoea (i.e., with very low risk of transmission). It is also
important to remember that most patients suspected with
EVD will not have EVD, but will have illness in need of
prompt treatment—commonly malaria—that may require
empiric treatment while awaiting diagnostic testing [84,
85]. Barriers to providing the standard of care to patients
suspected of EVD will repeatedly arise: “We don’t have
the capacity to do that… that is not part of our protocol.”
Do not accept this when it negatively influences patient
care. Instead, ask collectively “How can we safely solve this
challenge, now, for the benefit of this patient?”
For hospitals and intensive care units (ICUs) that will
provide definitive care for patients with EVD, there are
many Ebola-specific considerations well beyond the scope
of this review; however, a number deserve mention.
Fig. 2 Ebola treatment facility, Goderich, Sierra Leone—February 2015
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Table 3 Clinical management summary of 13 Ebola virus disease patients treated outside West Africa
Reference [76] [76] [42] [28, 79, 137] [78, 79, 82] [81, 82] [38] [25, 77] [28, 99] [81] [81] [82] [37]
Demographics
Gender M F M M M M M F M F F M M
Age (years) 33 59 36 51 43 42 38 44 33 26 29 44 43
Country of
infection
Liberia Liberia Sierra Leone Liberia Sierra Leone Liberia Sierra Leone Spain Liberia USA USA Sierra Leone Sierra Leone
Country
providing care
USA USA Germany USA USA USA Germany Spain USA USA USA USA Switzerland
Hospital admission
Admission date 2 Aug 2014 5 Aug 2014 27 Aug 2014 5 Sep 2014 9 Sep 2014 30 Sep 2014 3 Oct 2014 6 Oct 2014 6 Oct 2014 11 Oct 2014 14 Oct 2014 15 Nov 2014 21 Nov 2014
Days from
diagnosis to
evacuation
7 10 4 7 2 N/A 5 0 5 N/A N/A 6 4
Hospital LOS 19 14 30 20 41 8 47 30 16 13 14 3 15
Vital status Survived Survived Survived Survived Survived Died Survived Survived Survived Survived Survived Died Survived
Critical care therapies
Central line N N Y Y Y Y Y N Y Y N Y Y
Vasopressors N N N N Y Y Y N N N N Y N
Oxygen Y Y Y Y Y Y Y Y N N N Y N
NIV (d, days) N N Y (8d) N N N Y (1d) N N N N N N
MV (d, days) N N N N Y (17d) Y (5d) Y (13d) N N N N Y (3d) N
CRRT (d, days) N N N N Y (24d) Y (5d) Y (18d) N N N N Y (3d) N
IHD (d, days) N N N N N N Y (10d) N N N N N N
Experimental therapies
Convalescent
plasma
Y N N Y Y N N Y Y Y Y Y N
ZMapp/ZMab Y Y N N N N N Y N Y N Y Y
Brincidofovir N N N N N Y N N Y Y Y N N
Favipiravir N N Y N N N Y Y N N N N Y
TKM N N Y Y Y N N N N Y N N N
Other N/A N/A N/A N/A N/A N/A Amiodarone,
FX06
N/A N/A N/A N/A N/A N/A
CRRT continuous renal replacement therapy; F female, IHD intermittent hemodialysis, LOS length of stay, M male, MV invasive mechanical ventilation, N/A not available, NIV non-invasive ventilation, TKM TKM-Ebola,
small interfering ribonucleic acids (siRNA) produced by Tekmira
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Hospitals and ICUs will generally need to mould EVD
planning to the local environment, and seek out the ex-
perience, guidance, protocols, and training from those
who have substantial clinical and operational experience
(Figs. 3, 4) [64, 86].
Second, the physical environment of a proposed Ebola
treatment unit is a critical component of care. Ideally,
there should be a large available physical space, sufficient
for multiple isolation rooms, with very generously sized
antechamber areas for donning and doffing, and a
shared area from where clinical observation can occur
(Fig. 4). There should be sufficient adjoining space to
house dedicated diagnostic (e.g., portable radiograph and
ultrasound machines, potentially point-of-care labora-
tory devices) and therapeutic (intravenous pumps, mech-
anical ventilator and circuits, dialysis machine and
supplies) equipment. There should be ample nearby
space to house packaged soiled PPE and medical waste
that allows pick-up and proper disposal.
Third is the necessity for sufficiently numerous and
trained inter-professional team of clinical (nurses, physi-
cians, respiratory therapists, others) and patient support
staff (coordinators, monitors, cleaners, patient transpor-
tation services, diagnostic and laboratory staff, and so
forth), who are well practiced in the institutional Ebola
care plan and their specific roles. Whether this team is
led by infectious disease or critical care specialists, or
both, is likely less important than establishing an inter-
disciplinary model of continuity care throughout the
hospital stay, oftentimes in a single geographic location
that is institutionally appropriate.
Fourth, while EVD is accompanied by an increasingly
well-characterized clinical gastrointestinal syndrome
Fig. 3 Ebola treatment facility, Royal Free Hospital, London,
UK—September 2014
Fig. 4 Emory University Hospital special isolation unit. (1) The private patient rooms resemble intensive acre unit rooms, with adjustable beds,
intravenous drips, and monitors. Every procedure a patient could need, from mechanical ventilation to hemodialysis, can be performed in the unit.
(2) Medical staff who are providing direct patient care use a locker room to change into full-body protective suits and masks, which shield them from
blood and bodily fluids. (3) Family members are able to speak with patients through glass windows in the unit; patients have access to phones and
laptop computers. (4) A dedicated lab was built specifically for the use with the isolation unit that has the capacity to perform blood counts, routine
chemistries, blood gas measurements, urinalysis, and tests for a variety of infectious agents. (5) All liquid waste is disinfected and flushed,
and disposable waste is autoclaved and incinerated. At the peak of an Ebola patient’s illness, up to 40 bags a day of medical waste were produced
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leading to fluid, electrolyte, and acid-base imbalance
with multisystem organ dysfunction, there are no Ebola-
specific therapies yet to be proven effective. However, in-
tensive care medicine comprises experiential and
evidence-based organ-supportive care, which should
guide the care of patients with EVD—attention to fluid,
electrolyte and acid-base balance, initiation of empiric
and specific anti-infective therapy, and support for renal
injury and respiratory failure as occurs for other poten-
tially self-limited and survivable illnesses. Among pa-
tients with EVD treated in the USA and Europe, 41 %
were deemed to have critical illness with 70 % receiving
supplemental oxygen, 22 % with acute respiratory dis-
tress syndrome, 26 % invasive mechanical ventilation,
30 % intravenous vasoactive medications, and 19 % re-
quiring dialysis [40].
For the most severely ill patients, clinical judgment is
always necessary to balance risks and benefits of certain
resuscitation strategies, including the initiation of car-
diopulmonary resuscitation (CPR) [28, 87]. While there
is a lack of clinical experience with CPR in EVD pa-
tients, it may be a reasonable consideration while cor-
recting reversible abnormalities (i.e., hypoxia, severe
electrolyte disturbance, arrhythmias) in settings where
the option for advanced life-support exists. The decision
to provide CPR should be guided by its medical indication
and utility in that context, the ability to provide effective
CPR, and the safety of those providing care including
safe donning and doffing of PPE, in addition to patient
preferences [88, 89].
Fifth, as with all critical illness, medical technical care
is only one dimension of our support for patients and
their families. Patients with EVD and their families require
mechanisms to stay in audio and visual contact throughout
the illness—ideally visual contact through transparent bar-
riers or at safe distance, or direct contact with supervised
donning and doffing of PPE—in addition to substantial
psychosocial support during and after EVD.
Ebola-specific pharmacological prevention and
therapeutics
Current EVD treatment focuses on supportive care [70]
as there are no specific treatment options yet to be
proven effective [70, 90, 91]. A number of Ebola-specific
treatment strategies have undergone preliminary clinical
trial investigation, including convalescent plasma, Favi-
piravir, Brincidofovir and TMK-130803 [92–97]. Trans-
fusion of convalescent whole blood or plasma donated
by EVD survivors has been used in this and prior EVD
outbreaks [98] in an uncontrolled or compassionate-use
basis [25, 79, 81, 99], and in animal models [100, 101].
One of three clinical trials of convalescent plasma ther-
apy [94] has been completed and reported [102]. In this
nonrandomized comparison to historical controls,
transfusion of up to 500 ml convalescent plasma with
unknown levels of neutralizing antibodies in 84 patients
with confirmed EVD was not associated with a signifi-
cant improvement in survival. While there were no ser-
ious adverse reactions in this trial, transfusion-related
acute lung injury was described during convalescent
plasma therapy in Spain [25]. Favipiravir (Toyama,
Japan) [103], a pre-existing influenza virus inhibitor, has
been administered for compassionate use outside West
Africa [37, 38, 42]. In a multicenter, nonrandomized
clinical trial in Guinea [104], 111 patients receiving Favi-
piravir had similar survival to that based upon historical
control patients. The trial authors suggested that Favipir-
avir should be further studied in patients with medium
to high viremia, but not in those with very high viremia
[105]. Brincidofovir (Chimerix, USA), a nucleotide ana-
log that inhibits RNA-polymerase with in vitro activity
against Ebola [106], was administered to a small number
of EVD patients for uncontrolled compassionate use
[42, 79, 81, 99] and was tested in a phase 2 clinical trial
in Liberia [95] that was stopped after the manufacturer
withdrew study support [107]. TKM-130803 is a formula-
tion of lipid-nanoparticle-encapsulated small interfering
ribonucleic acids (siRNA) targeting two proteins involved
in Ebola virus transcription and replication (Tekmira,
USA, Canada). It was used in nonhuman primate Ebola
virus infection as a postexposure treatment strategy
[108] and in patients medically evacuated from West
Africa in uncontrolled compassionate use [79, 81].
However, a phase 2 clinical trial (RAPIDE-TKM) in
Sierra Leone [96] was halted according to pre-established
stopping rules [109].
ZMapp, a monoclonal antibody cocktail (Leafbio,
USA) [110], has been used under the emergency investi-
gational new drug approvals from the Food and Drug
Administration in patients treated in the USA, West
Africa, and Western Europe [40, 76, 111]. ZMapp treat-
ment of rhesus macaques resulted in 100 % survival even
when started 5 days after lethal EBOV infection [110]. In
the only randomized controlled trial of an investigational
therapeutic for EVD, ZMapp plus standard of care was
compared to standard of care alone for EVD patients in
four countries, including the three most impacted West
African countries. Due to the decline in EVD cases, this
unblinded ZMapp randomized controlled trial only
enrolled 72 of the prespecified target goal of 200 EVD pa-
tients; data were analyzed for 71 EVD patients, and mor-
tality in the ZMapp treatment group was 22 % versus
37 % in the untreated group, but this difference was not
statistically significant [112, 113].
The open-label, uncontrolled, and selected administra-
tion of other agents such as amiodarone [114], HMG-
CoA reductase inhibitors, and angiotensin II receptor
antagonists [115], and therapies to counteract vascular
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leak (FX06) [38] preclude any conclusions. In an obser-
vational study examining temporal trends in mortality
among patients with EVD in one ETU in Guinea, 125 of
194 (64.4 %) patients receiving artemether–lumefantrine
for malaria prophylaxis died as compared with 36 of 71
patients receiving artesunate–amodiaquine (50.7 %).
In adjusted analyses, the risk ratio was 0.69 (95 %
confidence interval, 0.54 to 0.89), with a stronger effect
observed among patients without malaria [116]. These
findings have not been confirmed in a randomized
clinical trial.
Two vaccine candidates demonstrated efficacy in
nonhuman primates [92, 117, 118]. A recombinant,
replication-competent vesicular stomatitis virus-based
vaccine expressing a surface glycoprotein of Zaire ebola-
virus rVSVΔG-EBOV-GP (rVSV) [118, 119] was evaluated
in an open-label, ring vaccination trial involving 7651
people in 90 clusters, randomized to immediate or delayed
(21 days) administration. The vaccine was well tolerated
and in the immediate vaccination group there were
no new EVD cases while in the delayed vaccination
group there were 16 EVD cases [120]. Another candidate
vaccine, cAd3-EBOV (cAd3) [117] remains under investi-
gation [92, 121]. Other vaccine candidates are also under
development and evaluation [122, 123].
Post-exposure Prophylaxis
Several healthcare personnel received post-exposure
prophylaxis with different interventions, including a
candidate Ebola vaccine, following potential high-risk
exposures to Ebola virus; although Ebola virus disease
did not occur in these individuals, no conclusions can be
made about the effectiveness of these uncontrolled inter-
ventions [124–126].
Ethical challenges in caring for patients with
Ebola virus disease
Each of the commonly applied four principles of medical
bioethics faces numerous threats in treating patients
with EVD [87]. A symptomatic patient’s autonomy to
not seek treatment (and not be isolated) is weighed
against the threat of disease transmission by staying in
the community. The injustice of treatment variability,
across regions and over time, places patients at differen-
tial risk of death. In acting beneficently, healthcare
workers inherently place themselves at some risk. A nat-
ural response is to balance that risk with the duty to
help. This frequently conspires against greater numbers
of health workers responding to an Ebola outbreak. The
duty to nonmaleficence, doing no harm, is a daily con-
undrum, through potential delays in routine diagnostic
work-up for common illnesses because of a lack of diag-
nostic testing, or, in resource-constrained environments,
inadequate space to separate potentially infectious suspect
patients along a gradient of risk.
Post-Ebola syndrome
With over 11,000 EVD survivors, there is increased recog-
nition of a post-Ebola syndrome in the convalescent
period, characterized by mental health and cognitive
sequelae, chronic headaches, insomnia, arthralgias, audi-
tory disturbances, and ocular effects including sight-
threatening uveitis [127–132]. It is uncertain whether
these manifestations are due to direct viral cytopathic
effect in immune-privileged compartments or postin-
fectious immune-mediated inflammation [133–135].
Research directions
Although this EVD outbreak narrowed some knowledge
gaps, pathophysiology and the immunological response to
acute infection and convalescence is still minimally char-
acterized. Access to rapid point-of-care EVD diagnostic
capacity to differentiate between other common febrile
illnesses [136] is critical because the early presentation of
EVD has a broad differential diagnosis [5, 7, 34]. Labora-
tory testing to identify prognostic indicators could help
guide clinical care. Evaluation of specific antiviral therap-
ies is critical as is evaluation of commonly used treatments
for which there is still very limited evidence (e.g., empiric
antibiotics, anti-diarrheal agents, and fluid replacement
composition and volume). The safety and functionality of
PPE must be improved. Standardized, easy-to-use clinical
charting and human resources for data entry should be
made available to support cohort studies and clinical trials.
While it seems intuitive that provision of advanced
supportive and critical care improves patient outcomes,
operationalizing and evaluating increased levels of care to
resource-challenged environments is needed. Prepared
research protocols that can be rapidly adapted to country-
specific settings and quickly implemented could reduce
research delays in future outbreaks. Following patients
who survive EVD is important to better characterize
immune correlates of virus clearance and host genetic
factors that contribute to survival, and to better address
morbidity of the post-Ebola syndrome.
Conclusions
The provision of advanced supportive and critical care
for EVD patients, while challenging, is possible in both
West African and more developed healthcare settings.
Creating and evaluating context-appropriate intensive
care capacity is a knowledge translation priority. The
experience of this outbreak emphasizes that, in addition
to evaluating specific medical treatments, improving the
global capacity to provide supportive critical care to
patients with severe illness may be associated with the
greatest opportunity to improve patient outcomes.
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